Observational studyPediatric nephrology (Berlin, Germany)2026
Kidney and blood pressure sequelae after pediatric extracorporeal membrane oxygenation: a secondary analysis of the Kidney Injury During Membrane Oxygenation pediatric ECMO cohort.
Observational study in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundAcute kidney injury (AKI) is common in children treated with extracorporeal membrane oxygenation (ECMO) and is associated with increased morbidity and mortality. AKI may also increase the risk of long-term chronic kidney disease (CKD) and persistent kidney dysfunction. Hospital discharge kidney dysfunction (HDKD) or the need for antihypertensive medication may further be associated with long-term CKD risk. This study aims to determine, in children treated with ECMO, the prevalence of HDKD and the use of antihypertensive medication at hospital discharge, as well as their associations with AKI during ECMO.
methodsRetrospective cohort study, including 6 pediatric centers. Children on ECMO between 2007-2011 ("KIDMO" cohort) surviving hospital discharge.
results354 children included, median age 25 days ([IQR] 2-457); ECMO mode: 61.2% veno-arterial (VA), 38.8% veno-venous (VV); ECMO indication: pulmonary (62.1%), cardiac (20.9%), extracorporeal cardiopulmonary resuscitation (ECPR) (17%). AKI occurred in 66.1%; 53.4% had ≥ Stage 2 AKI, including kidney support therapy (KST) and 35% received KST. 12.1% had HDKD and 33.2% were treated with anti-hypertensive medication at discharge. In patients with HDKD or treatment with anti-hypertensive medication, AKI was more frequent (HDKD: p < 0.0001; anti-hypertensive medication: p < 0.0001). In multivariable analysis, AKI and pediatric (vs. neonatal) age were associated with HDKD; cardiac or ECPR indication for ECMO and older age were associated with the need for anti-hypertensive medication at discharge.
conclusionsHDKD and anti-hypertensive medication at hospital discharge are common in pediatric ECMO survivors and associated with AKI. AKI is a known risk for long-term CKD and hypertension; systematic kidney health follow-up should be considered in these children.
Indexed as
Identifiers
41563418What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.